Vaxchora 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IA/0023/G 
This was an application for a group of variations. 
12/12/2023 
Annex II 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
A.4 - Administrative change - Change in the name 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
T/0021 
Transfer of Marketing Authorisation 
16/08/2023 
22/09/2023 
SmPC, 
Labelling and 
PL 
II/0020 
B.I.a.1.j - Change in the manufacturer of AS or of a 
14/09/2023 
n/a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
IB/0019/G 
This was an application for a group of variations. 
03/05/2023 
n/a 
B.II.z - Quality change - Finished product - Other 
variation 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
IB/0018/G 
This was an application for a group of variations. 
27/02/2023 
n/a 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
re-test period/storage period supported by real time 
data 
PSUSA/10862
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
/202206 
cholera vaccine, oral, live 
IB/0016 
B.I.z - Quality change - Active substance - Other 
22/12/2022 
n/a 
variation 
IA/0017 
B.II.b.3.a - Change in the manufacturing process of 
16/12/2022 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
II/0013 
Type II - C.I.4, to update Section 6.6 of the SmPC to 
21/07/2022 
04/07/2023 
SmPC, 
The SmPC section 6.6 has been updated as follows: to add 
Labelling and 
the use of carbonated bottled water to reconstitute the 
PL 
vaccine in addition to non-carbonated bottled water 
The PL have been updated accordingly. 
add the use of carbonated bottled water to 
reconstitute the vaccine in addition to non-
carbonated bottled water. The package leaflet and 
labelling are updated accordingly. 
The applicant took the opportunity to submit a 
corrected Annex A in all languages, which currently 
presents an inconsistency in the way the strength 
was stated at MAA approval (as detailed in SmPC). 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/10862
Periodic Safety Update EU Single assessment - 
07/07/2022 
n/a 
PRAC Recommendation - maintenance 
/202112 
cholera vaccine, oral, live 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0014 
C.I.11.z - Introduction of, or change(s) to, the 
20/05/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0011/G 
This was an application for a group of variations. 
10/02/2022 
n/a 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
PSUSA/10862
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
/202106 
cholera vaccine, oral, live 
IB/0010 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
22/12/2021 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
II/0009 
B.II.d.1.e - Change in the specification parameters 
16/12/2021 
n/a 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
PSUSA/10862
Periodic Safety Update EU Single assessment - 
08/07/2021 
n/a 
PRAC Recommendation - maintenance 
/202012 
cholera vaccine, oral, live 
IA/0007 
A.7 - Administrative change - Deletion of 
04/05/2021 
02/08/2022 
Annex II and 
manufacturing sites 
PL 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0003/G 
This was an application for a group of variations. 
28/01/2021 
26/02/2021 
SmPC, Annex 
Please refer to Scientific Discussion ‘Vaxchora-H-C-003876-
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
and PL 
II, Labelling 
II-0003-G’ 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
PSUSA/10862
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202006 
cholera vaccine, oral, live 
IB/0005 
B.I.b.2.e - Change in test procedure for AS or 
05/01/2021 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0002/G 
This was an application for a group of variations. 
29/06/2020 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
IAIN/0001 
A.5.a - Administrative change - Change in the name 
20/05/2020 
26/02/2021 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 6/6 
 
 
 
 
 
 
 
